Clinical evaluation of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis: efficacy, safety, patient experience and adherence

References

• Høglund RA, Maghazachi AA. Multiple sclerosis and the role of immune cells. World J Exp Med. 2014;4:27–37. doi:10.5493/wjem.v4.i3.2725254187
   PubMedGoogle Scholar
• Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2016;13:25. doi:10.1038/nrneurol.2016.18727934854
   PubMed Web of Science ®Google Scholar
• Dubey D, Kieseier BC, Hartung HP, et al. Dimethyl fumarate in relapsing–remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Rev Neurother. 2015;15:339–346. doi:10.1586/14737175.2015.102575525800129
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and Progression of Disability in Multiple Sclerosis. N Engl J Med. 2000;343:1430–1438. doi:10.1056/NEJM20001116343200111078767
   PubMed Web of Science ®Google Scholar
• Costello K, Halper J, Kalb R, Skutnik L, Rapp R. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence. A consensus paper by the multiple sclerosis coalition. 2015 Available from: http://www.nationalmssociety.org/getmedia/5ca284d3-fc7c-4ba5-b005-ab537d495c3c/DMT_Consensus_MS_Coalition_color. Accessed August 20, 2019.
   Google Scholar
• FDA approves new oral drug to treat multiple sclerosis [online]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-oral-drug-treat-multiple-sclerosis. Accessed 82, 2019.
   Google Scholar
• FDA approves new oral treatment for multiple sclerosis [online]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-oral-treatment-multiple-sclerosis. Accessed 82, 2019.
   Google Scholar
• Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clinic Proc. 2014;89:225–240. doi:10.1016/j.mayocp.2013.11.002
   PubMed Web of Science ®Google Scholar
• Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence. 2010;4:1–9.20165593
   PubMed Web of Science ®Google Scholar
• Caon C, Namey M, Meyer C, et al. Prevention and management of infusion-associated reactions in the comparison of alemtuzumab and Rebif(®) efficacy in multiple sclerosis (CARE-MS) program. Int J MS Care. 2015;17:191–198. doi:10.7224/1537-2073.2014-03026300705
   PubMedGoogle Scholar
• Agashivala N, Wu N, Abouzaid S, et al. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. BMC Neurol. 2013;13:138. doi:10.1186/1471-2377-13-20224093542
   PubMed Web of Science ®Google Scholar
• Bergvall N, Petrilla AA, Karkare SU, et al. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. J Med Econ. 2014;17:696–707. doi:10.3111/13696998.2014.94042225019581
   PubMedGoogle Scholar
• Mrowietz U, Barker J, Boehncke W-H, et al. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. J Eur Acad Dermatol Venereol. 2018;32:3–14. doi:10.1111/jdv.15218
   PubMed Web of Science ®Google Scholar
• Ingwersen J, Aktas O, Hartung H-P. Advances in and algorithms for the treatment of relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016;13:47–57. doi:10.1007/s13311-015-0412-426701666
   PubMed Web of Science ®Google Scholar
• Schmidt MM, Dringen R. Fumaric acid diesters deprive cultured primary astrocytes rapidly of glutathione. Neurochem Int. 2010;57:460–467. doi:10.1016/j.neuint.2010.01.00620096739
   PubMed Web of Science ®Google Scholar
• Linker RA, Lee D-H, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134:678–692. doi:10.1093/brain/awq38621354971
   PubMed Web of Science ®Google Scholar
• Nguyen T, Sherratt PJ, Pickett CB. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol. 2003;43:233–260. doi:10.1146/annurev.pharmtox.43.100901.14022912359864
   PubMed Web of Science ®Google Scholar
• Wang Q, Chuikov S, Taitano S, et al. Dimethyl fumarate protects neural stem/progenitor cells and neurons from oxidative damage through Nrf2-ERK1/2 MAPK pathway. Int J Mol Sci. 2015;16:13885. doi:10.3390/ijms16061388526090715
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Brück J, Kellerer C, et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med. 2011;208:2291–2303. doi:10.1084/jem.2010097721987655
   PubMed Web of Science ®Google Scholar
• Peng H, Guerau-de-Arellano M, Mehta VB, et al. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem. 2012;287:28017–28026. doi:10.1074/jbc.M112.38338022733812
   PubMed Web of Science ®Google Scholar
• Borgers M, Beyaert R, Borghmans I, et al. Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of NF-κB1, but not rela in normal human dermal fibroblast cells. J Invest Dermatol. 2001;116:124–130. doi:10.1046/j.1523-1747.2001.00211.x11168807
   PubMed Web of Science ®Google Scholar
• Lin SX, Lisi L, Dello Russo C, et al. The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro. 2011;3:e00055. doi:10.1042/AN2010003321382015
   PubMed Web of Science ®Google Scholar
• Treumer F, Zhu K, Gläser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol. 2003;121:1383–1388. doi:10.1111/j.1523-1747.2003.12605.x14675187
   PubMed Web of Science ®Google Scholar
• Wu Q, Wang Q, Mao G, Dowling CA, Lundy SK, Mao-Draayer Y. Dimethyl fumarate selectively reduces memory T cells and shifts the balance between Th1/Th17 and Th2 in multiple sclerosis patients. J Immunol. 2017;198:3069–3080. doi:10.4049/jimmunol.160153228258191
   PubMed Web of Science ®Google Scholar
• Gross CC, Schulte-Mecklenbeck A, Klinsing S, Posevitz-Fejfár A, Wiendl H, Klotz L. Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. Neurology. 2016;3:e183. doi:10.1212/NXI.0000000000000183
   Web of Science ®Google Scholar
• Parodi B, Rossi S, Morando S, et al. Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta Neuropathol. 2015;130:279–295. doi:10.1007/s00401-015-1422-325920452
   PubMed Web of Science ®Google Scholar
• Chen H, Assmann JC, Krenz A, et al. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE. J Clin Invest. 2014;124:2188–2192. doi:10.1172/JCI7215124691444
   PubMed Web of Science ®Google Scholar
• Litjens NHR, Burggraaf J, Van Strijen E, et al. Pharmacokinetics of oral fumarates in healthy subjects. Br J Clin Pharmacol. 2004;58:429–432. doi:10.1111/j.1365-2125.2004.02145.x15373936
   PubMed Web of Science ®Google Scholar
• Rostami-Yazdi M, Clement B, Mrowietz U. Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients. Arch Dermatol Res. 2010;302:531–538. doi:10.1007/s00403-010-1061-420574745
   PubMed Web of Science ®Google Scholar
• Sheikh SI, Nestorov I, Russell H, et al. Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers. Clin Ther. 2013;35:1582–1594.e1589. doi:10.1016/j.clinthera.2013.08.00924139424
   PubMed Web of Science ®Google Scholar
• Idec B. Tecfidera (dimethyl Fumarate) Prescribing Information. Cambridge (MA): Biogen Idec; 2013.
   Google Scholar
• Edwards K, Penner N, Rogge M, Sheikh S, Zhu B. A pharmacokinetic study of delayed-release dimethyl fumarate to evaluate cerebrospinal fluid penetration in patients with secondary progressive multiple sclerosis. London: Sage Publications Lted. Mult Scler J. 2016;22:784–785.
   Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled Phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098–1107. doi:10.1056/NEJMoa111428722992073
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled Phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087–1097. doi:10.1056/NEJMoa120632822992072
   PubMed Web of Science ®Google Scholar
• Kappos L, Giovannoni G, Gold R, et al. Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis. Eur J Neurol. 2015;22:664–671. doi:10.1111/ene.1262425557371
   PubMed Web of Science ®Google Scholar
• Viglietta V, Miller D, Bar-Or A, et al. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Ann Clin Transl Neurol. 2015;2:103–118. doi:10.1002/acn3.14825750916
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Gold R, Kappos L, et al. Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: integrated analysis of DEFINE and CONFIRM. Mult Scler J. 2016;2:2055217316634111. doi:10.1177/2055217316634111
   Google Scholar
• Arnold DL, Gold R, Kappos L, et al. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol. 2014;261:2429–2437. doi:10.1007/s00415-014-7504-725270680
   PubMed Web of Science ®Google Scholar
• Dupuy SL, Tauhid S, Hurwitz S, Chu R, Yousuf F, Bakshi R. The effect of dimethyl fumarate on cerebral gray matter atrophy in multiple sclerosis. Neurol Ther. 2016;5:215–229. doi:10.1007/s40120-016-0054-427744504
   PubMedGoogle Scholar
• Havrdova E, Giovannoni G, Gold R, et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing–remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol. 2017;24:726–733. doi:10.1111/ene.1327228328179
   PubMed Web of Science ®Google Scholar
• Gold R, Arnold DL, Bar-Or A, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study. Mult Scler J. 2017;23:253–265. doi:10.1177/1352458516649037
   PubMed Web of Science ®Google Scholar
• Berger T, Brochet B, Confalonieri P, et al. Effectiveness of delayed-release dimethyl fumarate on clinical disease activity and patient-reported outcomes in patients with relapsing-remitting multiple sclerosis in the real-world setting: a multicentre, open-label study (PROTEC). London: Sage Publications Ltd. Mult Scler J. 2016;22:298–299.
   Google Scholar
• Everage NJ, Prada C, Liu S, et al. Safety and efficacy of delayed-release dimethyl fumarate in multiple sclerosis patients treated in routine medical practice: interim analysis of ESTEEM (P6.333). Neurology. 2017;88:P6.333. doi:10.1212/WNL.0000000000003693
   Web of Science ®Google Scholar
• Smoot K, Spinelli KJ, Stuchiner T, et al. Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center. Mult Scler J. 2018;24:942–950. doi:10.1177/1352458517709956
   PubMed Web of Science ®Google Scholar
• Longbrake EE, Naismith RT, Parks BJ, Wu GF, Cross AH. Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance. Mult Scler J. 2015;1:2055217315596994. doi:10.1177/2055217315596994
   Google Scholar
• Weldring T, Smith SMS. Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs). Health Serv Insights. 2013;6:61–68. doi:10.4137/HSI.S1109325114561
   PubMedGoogle Scholar
• Nortvedt MW, Riise T. The use of quality of life measures in multiple sclerosis research. Mult Scler J. 2003;9:63–72. doi:10.1191/1352458503ms871oa
   PubMed Web of Science ®Google Scholar
• Kita M, Fox RJ, Phillips JT, et al. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing–remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler J. 2014;20:253–257. doi:10.1177/1352458513507818
   PubMed Web of Science ®Google Scholar
• Kappos L, Gold R, Arnold DL, et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: the DEFINE study. Mult Scler J. 2014;20:243–252. doi:10.1177/1352458513507817
   PubMed Web of Science ®Google Scholar
• Lee A, Pike J, Edwards MR, Petrillo J, Waller J, Jones E. Quantifying the benefits of dimethyl fumarate over β interferon and glatiramer acetate therapies on work productivity outcomes in MS patients. Neurol Ther. 2017;6:79–90. doi:10.1007/s40120-016-0061-528093681
   PubMed Web of Science ®Google Scholar
• Phillips JT, Selmaj K, Gold R, et al. Clinical significance of gastrointestinal and flushing events in patients with multiple sclerosis treated with delayed-release dimethyl fumarate. Int J MS Care. 2015;17:236–243. doi:10.7224/1537-2073.2014-06926472945
   PubMedGoogle Scholar
• Baharnoori M, Gonzalez CT, Chua A, et al. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count. Mult Scler Relat Disord. 2018;20:51–57. doi:10.1016/j.msard.2017.12.00329304497
   PubMed Web of Science ®Google Scholar
• Lehmann-Horn K, Penkert H, Grein P, et al. PML during dimethyl fumarate treatment of multiple sclerosis: how does lymphopenia matter? Neurology. 2016;87:440–441. doi:10.1212/WNL.000000000000290027343070
   PubMed Web of Science ®Google Scholar
• Gieselbach R-J, Muller-Hansma AH, Wijburg MT, et al. Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. J Neurol. 2017;264:1155–1164.28536921
   PubMed Web of Science ®Google Scholar
• Motte J, Kneiphof J, Straßburger-Krogias K, et al. Detection of JC virus archetype in cerebrospinal fluid in a MS patient with dimethylfumarate treatment without lymphopenia or signs of PML. J Neurol. 2018;265:1880–1882. doi:10.1007/s00415-018-8931-729948248
   PubMed Web of Science ®Google Scholar
• Muñoz MA, Kulick CG, Kortepeter CM, Levin RL, Avigan MI. Liver injury associated with dimethyl fumarate in multiple sclerosis patients. Mult Scler J. 2017;23:1947–1949. doi:10.1177/1352458516688351
   PubMed Web of Science ®Google Scholar
• Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther. 2011;28:51–61. doi:10.1007/s12325-010-0093-721153000
   PubMed Web of Science ®Google Scholar
• Gold R, Schlegel E, Elias-Hamp B, et al. Incidence and mitigation of gastrointestinal events in patients with relapsing–remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE). Ther Adv Neurol Disord. 2018;11:1756286418768775. doi:10.1177/175628641876877529707040
   PubMed Web of Science ®Google Scholar
• Fox EJ, Vasquez A, Grainger W, et al. Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing forms of multiple sclerosis (MANAGE). Int J MS Care. 2016;18:9–18. doi:10.7224/1537-2073.2014-10126917993
   PubMedGoogle Scholar
• Eriksson I, Cars T, Piehl F, Malmström RE, Wettermark B, von Euler M. Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study. Eur J Clin Pharmacol. 2018;74:219–226. doi:10.1007/s00228-017-2366-429128972
   PubMed Web of Science ®Google Scholar
• Nicholas J, Boster A, Wu N, et al. Comparative effectiveness of delayed-release dimethyl fumarate versus fingolimod and teriflunomide on risk of relapse (P6.375). Neurology. 2017;88:P6.375. doi:10.1212/WNL.0000000000003693
   Web of Science ®Google Scholar
• Johnson KM, Zhou H, Lin F, Ko JJ, Herrera V. Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year. J Manag Care Spec Pharm. 2017;23:844–852. doi:10.18553/jmcp.2017.23.8.84428737986
   PubMedGoogle Scholar
• Vollmer B, Nair KV, Sillau SH, Corboy J, Vollmer T, Alvarez E. Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: two-year experience. Mult Scler J. 2017;3:2055217317725102. doi:10.1177/2055217317725102
   Google Scholar
• Srivastava K, Arora A, Kataria A, Cappelleri JC, Sadosky A, Peterson AM. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence. 2013;7:419–434. doi:10.2147/PPA.S4464623737662
   PubMed Web of Science ®Google Scholar
• Utz KS, Hoog J, Wentrup A, et al. Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis. Ther Adv Neurol Disord. 2014;7:263–275. doi:10.1177/175628561455533525371708
   PubMed Web of Science ®Google Scholar
• Phillips JT, Hutchinson M, Fox R, Gold R, Havrdova E. Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: experiences of an international panel. Mult Scler Relat Disord. 2014;3:513–519. doi:10.1016/j.msard.2014.03.00325877064
   PubMed Web of Science ®Google Scholar
• Sammarco C, Laing L, Herbert J. Strategies to reduce adverse events related to oral dimethyl fumarate. London: Sage Publications Ltd. Mult Scler J.2014;20:206.
   Google Scholar
• Mäurer M, Voltz R, Begus-Nahrmann Y, Schmid B, Niemczyk G, Kieseier B. Adherence project with German MS-patients: can an approach of individualized patient counseling improve adherence? London: Sage Publications Ltd. Mult Scler J.2014;20:203–203.
   Web of Science ®Google Scholar
• Theodore Phillips J, Erwin AA, Agrella S, et al. Consensus management of gastrointestinal events associated with delayed-release dimethyl fumarate: a delphi study. Neurol Ther. 2015;4:137–146. doi:10.1007/s40120-015-0037-x26525536
   PubMedGoogle Scholar
• O’Gorman J, Russell HK, Li J, Phillips G, Kurukulasuriya NC, Viglietta V. Effect of aspirin pretreatment or slow dose titration on flushing and gastrointestinal events in healthy volunteers receiving delayed-release dimethyl fumarate. Clin Ther. 2015;37:1402–1419.e1405. doi:10.1016/j.clinthera.2015.03.02825999183
   PubMed Web of Science ®Google Scholar
• Koulinska I, Riester K, Chalkias S, Edwards MR. Effect of bismuth subsalicylate on gastrointestinal tolerability in healthy volunteers receiving oral delayed-release dimethyl fumarate: PREVENT, a randomized, multicenter, double-blind, placebo-controlled study. Clin Ther. 2018;40:2021–2030. e2021. doi:10.1016/j.clinthera.2018.10.01330447891
   PubMed Web of Science ®Google Scholar
• Tornatore C, Amjad F. attenuation of dimethyl fumarate-related gastrointestinal symptoms with montelukast (P7.251). Neurology. 2014;82:P7.251. doi:10.1212/WNL.0000000000000513
   Web of Science ®Google Scholar
• Wong K-H, Marini E, Nguyen T, et al. Dimethyl fumarate in relapsing remitting multiple sclerosis: 24 months observations of the effects of dose reduction on lymphopenia (P6.347). Neurology. 2018;90:P6.347. doi:10.1212/WNL.0000000000005560
   Web of Science ®Google Scholar
• Miclea A, Leussink VI, Hartung HP, Gold R, Hoepner R. Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study. J Neurol. 2016;263:1626–1632. doi:10.1007/s00415-016-8175-327260297
   PubMed Web of Science ®Google Scholar
• Sejbaek T, Nybo M, Petersen T, Illes Z. Real-life persistence and tolerability with dimethyl fumarate. Mult Scler Relat Disord. 2018;24:42–46. doi:10.1016/j.msard.2018.05.00729906666
   PubMed Web of Science ®Google Scholar